Filing Details

Accession Number:
0001548538-14-000011
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-06-11 17:27:44
Reporting Period:
2014-06-09
Filing Date:
2014-06-11
Accepted Time:
2014-06-11 17:27:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1302573 Oncomed Pharmaceuticals Inc OMED Pharmaceutical Preparations (2834) 383572512
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1225446 P L A Viii Partners Entrepreneur Usvp 2735 Sand Hill Road
Menlo Park CA 94025
No No Yes No
1225448 P L B Viii Partners Entrepreneur Usvp 2735 Sand Hill Road
Menlo Park CA 94025
No No Yes No
1225484 C L L Viii Group Management Presidio 2735 Sand Hill Road
Menlo Park CA 94025
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-06-09 5,476 $24.62 30,606 No 4 S Indirect Directly owned by EP VIII-A
Common Stock Disposition 2014-06-09 2,776 $24.62 15,513 No 4 S Indirect Directly owned by EP VIII-B
Common Stock Disposition 2014-06-10 3,186 $24.48 21,944 No 4 S Indirect Directly owned by EP VIII-A
Common Stock Disposition 2014-06-10 1,614 $24.48 11,123 No 4 S Indirect Directly owned by EP VIII-B
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Directly owned by EP VIII-A
No 4 S Indirect Directly owned by EP VIII-B
No 4 S Indirect Directly owned by EP VIII-A
No 4 S Indirect Directly owned by EP VIII-B
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.21 to $24.99, inclusive for sales made on June 9, 2014, and prices ranging from $23.95 to $24.85, inclusive for sales made on June 10, 2014. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  2. The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein.